Clinical Trial Update: A Study to Determine the Absorption, Distribution, Metabolism, and Excretion of LBH589 [Phase 1]

View source ↗

Summary

A Phase 1 study to determine the absorption, distribution, metabolism, and excretion of LBH589 (panobinostat) in cancer patients with advanced solid tumors, inc…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hematologic Malignancies
• Lymphoma
• Solid Tumors

Drugs mentioned

• LBH589 (panobinostat)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Cancer Patients With Advanced Solid Tumors Including Lymphoma or Chronic Hematological Malignancies | Phase 1 | Status: COMPLETED